Tumor rejection antigens
AssigneeLudwig Institute for Cancer Research
InventorsLan-Qing Huang, Aline Van Pel, Francis Brasseur, Etienne De Plaen, Thierry Boon
Life of this patent
Estimating the term…
Abstract
Polypeptides comprising an unbroken sequence of amino acids from SEQ ID NO: 1 or 2, with an ability to complex with a major histocompatibility complex molecule type HLA-A2, and preferably HLA-A2.1.
Claims12
An isolated polypeptide consisting of an unbroken sequence of amino acids from SEQ ID NO:
- 1 that complexes with a major histocompatibility complex molecule type HLA-A2, wherein the amino acid sequence of said isolated polypeptide is not that set out in either of SEQ ID NOs:1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50), or FLLFKYQMK (SEQ ID NO:48), or FIEGYCTPE (SEQ ID NO:49), or CLGLSYDGL (SEQ ID NO:57).
An isolated polypeptide consisting of an unbroken sequence of amino acids from SEQ ID NO:
- 1, that elicits an immune response from human lymphocytes, wherein the amino acid sequence of said isolated polypeptide or protein is not that set out in either of SEQ ID NOs:
- 1 and 2, or that coded for by nucleotides 334-918 of SEQ ID NO:7, or GLEGAQAPL (SEQ ID NO:50), or FLLFKYQMK (SEQ ID NO:48), or FIEGYCTPE (SEQ ID NO:49), or CLGLSYDGL (SEQ ID NO:57).
An isolated nonapeptide consisting of an unbroken sequence of amino acids from SEQ ID NO:
- 1, wherein either the amino acid following the N-terminal amino acid is L and the C-terminal amino acid is L, V, or I, or the amino acid following the N-terminal amino acid is M and the C-terminal amino acid is I, other than a nonapeptide having the sequence CLGLSYDGL (SEQ ID NO:57), or GLEGAQAPL (SEQ ID NO:50).
An isolated nonapeptide having the amino acid sequence GLYDGMEHL (SEQ ID NO:42).
An isolated decapeptide having the amino acid sequence GLYDGMEHLI (SEQ ID NO:44).
Dependencies are inferred from the claim text.